University of Nottingham

Promethean Particles designs, develops, and manufactures inorganic nanoparticle dispersions for industrial applications, offering tailor-made solutions based on customer specifications. The company employs continuous hydrothermal synthesis to produce optimized dispersions and operates a multi-ton scale manufacturing capability of more than 1,000 tons per year. It serves sectors including printed electronics, nanocomposites, catalysts, metal-organic frameworks, healthcare, and green energy, and provides feasibility studies to tailor solutions to specific requirements. Founded in 2007 and based in Nottingham, United Kingdom, Promethean Particles combines proprietary processes with flexible, bespoke production to meet diverse industrial needs.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

PBD Biotech is a clinical-stage diagnostics company that develops phage-based tests for mycobacterial diseases in humans and animals. Its Actiphage platform enables detection of mycobacteria in milk and blood and differentiates viable from non-viable organisms, delivering rapid results with high sensitivity and specificity. The technology targets pathogens such as Mycobacterium bovis, which causes bovine tuberculosis, and Mycobacterium avium subsp. paratuberculosis, which affects livestock health and productivity. By enabling early, accurate identification of tuberculosis and related mycobacterial infections, PBD Biotech supports disease management in the agricultural sector and clinical contexts.

Alevin Therapeutics focuses on developing safe and effective medicines for patients with life-threatening diseases. Its primary focus is on targeted integrin therapies for high-need clinical areas such as fibrosis, including idiopathic pulmonary fibrosis, liver and kidney disease, and cancer.

Cheesecake Energy develops advanced thermal and compressed air energy systems to store renewable energy from intermittent sources, providing reliable power on demand.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a company focused on facilitating language learning for children through engaging storytelling. By employing their innovative Clockwork Methodology®, One Third Stories creates a unique experience where stories begin in English and transition into different languages, making the learning process enjoyable and accessible. The company offers a subscription box service that delivers these stories to parents and their children, enabling them to embark on a language learning adventure together. Through this approach, One Third Stories aims to make foreign language acquisition simple and fun for young learners.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a company focused on facilitating language learning for children through engaging storytelling. By employing their innovative Clockwork Methodology®, One Third Stories creates a unique experience where stories begin in English and transition into different languages, making the learning process enjoyable and accessible. The company offers a subscription box service that delivers these stories to parents and their children, enabling them to embark on a language learning adventure together. Through this approach, One Third Stories aims to make foreign language acquisition simple and fun for young learners.

Monica Healthcare, based in Nottingham, United Kingdom, is a manufacturer of advanced fetal monitoring devices aimed at improving obstetric care. Founded in 2005, the company specializes in innovative wearable technologies that utilize wireless systems to monitor maternal heart rate, fetal heart rate, and uterine activity. One of its key products is The Novii, a single-use wireless patch designed for both hospital and home use. Monica Healthcare's devices are intended to enhance the birth experience for midwives, labor and delivery nurses, and expectant mothers, while also facilitating access to obstetric services. In addition to its product offerings, the company provides training, repairs, and support services to its customers. Since 2017, Monica Healthcare has been operating as a subsidiary of GE Healthcare.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Monica Healthcare, based in Nottingham, United Kingdom, is a manufacturer of advanced fetal monitoring devices aimed at improving obstetric care. Founded in 2005, the company specializes in innovative wearable technologies that utilize wireless systems to monitor maternal heart rate, fetal heart rate, and uterine activity. One of its key products is The Novii, a single-use wireless patch designed for both hospital and home use. Monica Healthcare's devices are intended to enhance the birth experience for midwives, labor and delivery nurses, and expectant mothers, while also facilitating access to obstetric services. In addition to its product offerings, the company provides training, repairs, and support services to its customers. Since 2017, Monica Healthcare has been operating as a subsidiary of GE Healthcare.

Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, founded in 2002 by Professor Steve Howdle. The company specializes in developing innovative drug delivery technologies, including CriticalSorb for non-invasive nasal delivery and CriticalMix for sustained release injectable products. Its portfolio features several therapeutic products aimed at addressing significant medical needs, such as CP024, a nasal growth hormone for growth hormone deficiency, and CP046, a nasal formulation of teriparatide for osteoporosis treatment. Other products include an injectable human growth hormone and a sustained release formulation of Bevacizumab for age-related macular degeneration. Critical Pharmaceuticals employs unique methods, including the use of supercritical carbon dioxide to enhance drug encapsulation in regulatory-approved polymers. As of July 31, 2017, the company was placed under liquidation.